GlassScriptPhysician profile
Janelle Roethemeyer
NPI 1417938929
$924.40
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $53.24 · 2022: $57.70 · 2023: $130 · 2024: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.23 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $109.25 | 2019-2024 | |
| Novo Nordisk INC | $84.91 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Sumitomo Pharma America, INC. | $84.66 | 2023-2024 | Gemtesa |
| Helsinn Therapeutics (U.S.), INC. | $77.52 | 2019 | |
| Aclaris Therapeutics, INC. | $75.59 | 2019 | |
| Lilly USA, LLC | $55.74 | 2019-2022 | |
| Abbott Laboratories | $50.93 | 2019-2023 | Freestyle Libre 2 |
| Amgen INC. | $49.57 | 2019-2022 | |
| Abbvie INC. | $43.41 | 2023-2024 | Vraylar |
| Glaxosmithkline, LLC. | $39.75 | 2019-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $34.08 | 2023-2024 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $32.69 | 2019 | |
| Allergan, INC. | $29.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.61 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.72 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $17.70 | 2019 | |
| Dexcom, INC. | $16.33 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $15.74 | 2020 | |
| Sanofi Pasteur INC. | $13.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.15 | 2019 | |
| Amarin Pharma, INC. | $12.01 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janelle Roethemeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.